Comparable stake leader
Fairmount Funds Management LLC
SEC ownership of Spyre Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001636282.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
16 Apr 2026
- Public ticker
- SYRE on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Fairmount Funds Management LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Fairmount Funds Management LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
16 Apr 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001636282
- Issuer location
- Waltham, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Spyre Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Fairmount Funds Managemen...
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
16 Apr 2026
13D/G
3/4/5
13F
Lead comparable stake: 10%
13D/G row: Fairmount Funds Management LLC
Showing 1-8 of 50 holder rows.
Quick read
Fairmount Funds Management LLC leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Fairmount Funds Management LLC's linked filing trail.
Comparable ownership
Top 5
Fairmount Funds Management LLC
10%
BlackRock, Inc.
6.6%
RTW INVESTMENTS, LP
6.2%
PERCEPTIVE ADVISORS LLC
5%
Venrock Healthcare Capital Partne...
4.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC |
13D/G
3/4/5
13F
Peter Harwin · Director · Company
|
10%
|
$454,802,449
9,016,702 shares
|
+$45,891,321 | 16 Apr 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
6.6%
from 13D/G
|
$278,490,385
5,521,221 shares
|
— | 31 Mar 2026 |
| RTW INVESTMENTS, LP |
13F
13D/G
Company
|
6.2%
from 13D/G
|
$210,435,478
4,171,996 shares
|
— | 31 Mar 2026 |
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
Company
|
5%
|
$217,875,378
4,319,496 shares
|
+$88,006,350 | 15 Apr 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
4.6%
|
$40,335,429
2,685,448 shares
|
$0 | 31 Dec 2024 |
| TANG CAPITAL MANAGEMENT LLC |
13F
13D/G
Company
|
2.4%
from 13D/G
|
$95,442,568
1,892,200 shares
|
— | 31 Mar 2026 |
| FMR LLC |
13F
Company
|
14%
|
$594,234,851
11,781,024 shares
|
— | 31 Mar 2026 |
| Venrock Adviser, LLC |
13F
Company
|
4.3%
|
$185,893,997
3,685,448 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$20,709,108.
Buys
$0
Insiders: 0
Sells
$20,709,108
Insiders: 4
Net
-$20,709,108
Shares: -373,052
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 373,052
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 247,124 | $0 | $17,237,670 | -$17,237,670 |
| 3-6 | 0 | 47,500 | $0 | $1,686,665 | -$1,686,665 |
| 6-9 | 0 | 60,000 | $0 | $1,485,133 | -$1,485,133 |
| 9-12 | 0 | 18,428 | $0 | $299,639 | -$299,639 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 29 reporting-owner rows connected to Spyre Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
29
Largest Forms 3/4/5 holder
Cameron Turtle
Net 12M change
-$20,709,107
Latest report
03 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Cameron Turtle | Chief Executive Officer, Director | $42,652,405 | -$5,937,084 | -12% | Filing P/S | 01 Jun 2026 |
| Scott L. Burrows | Chief Financial Officer | $7,061,447 | -$2,196,397 | -24% | Filing P/S | 01 Jun 2026 |
| Michael Thomas Henderson | Director | $6,676,462 | -$5,952,050 | -47% | Filing P/S | 27 May 2026 |
| Jeffrey W. Albers | Director | $1,005,838 | Filing P/S | 27 May 2026 | ||
| Anthony G. Quinn | President & CEO, Director | $579,952 | Mixed | 16 Mar 2022 | ||
| Marcio Souza | Director | $63,900 | Mixed | 25 Aug 2022 | ||
| Sheldon Sloan | Chief Medical Officer | $0 | -$6,623,576 | -100% | Mixed | 03 Jun 2026 |
| Hunter C. Smith | Director | Mixed | 22 Jun 2023 | |||
| BAKER BROS. ADVISORS LP | Director | Mixed | 08 Jun 2021 | |||
| Alison Frances Lawton | Director | Mixed | 22 Jun 2023 | |||
| Russell J. Cox | Director | Mixed | 22 Jun 2023 | |||
| Armen Shanafelt | Director | Mixed | 07 Jun 2022 | |||
| Sandesh Mahatme | Director | Mixed | 07 Jun 2022 | |||
| Ivana Magovcevic-Liebisch | Director | Mixed | 22 Jun 2023 | |||
| Steven Weber | VP, Controller&Princ Acctg Off | Mixed | 17 Feb 2022 | |||
| Bryan Lawlis V | Director | Mixed | 07 Jun 2022 | |||
| James Paul Kastenmayer | General Counsel | Mixed | 23 Feb 2023 | |||
| Linda L. Neuman | Chief Medical Officer | Mixed | 23 Feb 2023 | |||
| Jeff Marc Goldberg | President and CEO, Director | Mixed | 29 Nov 2022 | |||
| Jonathan Alspaugh | President and CFO | Mixed | 22 Jun 2023 |
Recent insider transactions for Spyre Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sheldon Sloan | SYRE | Common Stock | Sale | -100% | $624,975 | $75.00 | -8,333 | 0 | 03 Jun 2026 | Direct |
| Sheldon Sloan | SYRE | Common Stock | Options Exercise | 8,333 | 8,333 | 03 Jun 2026 | Direct | |||
| Sheldon Sloan | SYRE | Stock Option (Right to Buy) | Options Exercise | -2.59% | -8,333 | 313,334 | 03 Jun 2026 | Direct | ||
| Cameron Turtle | SYRE | Common Stock | Sale | -2.45% | $1,056,486 | $70.43 | -15,000 | 597,540 | 01 Jun 2026 | Direct |
| Scott L. Burrows | SYRE | Common Stock | Sale | -7.11% | $532,937 | $71.06 | -7,500 | 97,994 | 01 Jun 2026 | Direct |
| Scott L. Burrows | SYRE | Common Stock | Options Exercise | 7.65% | 7,500 | 105,494 | 01 Jun 2026 | Direct | ||
| Scott L. Burrows | SYRE | Stock Option (Right to Buy) | Options Exercise | -1.96% | -7,500 | 374,857 | 01 Jun 2026 | Direct | ||
| Fairmount Funds Management LLC | SYRE | Stock Option (Right to Buy) | Award | 8,026 | 8,026 | 27 May 2026 | By Tomas Kiselak | |||
| Fairmount Funds Management LLC | SYRE | Stock Option (Right to Buy) | Award | 8,026 | 8,026 | 27 May 2026 | By Tomas Kiselak | |||
| Fairmount Funds Management LLC | SYRE | Stock Option (Right to Buy) | Award | 8,026 | 8,026 | 27 May 2026 | By Tomas Kiselak | |||
| Jeffrey W. Albers | SYRE | Stock Option (Right to Buy) | Award | 8,026 | 8,026 | 27 May 2026 | Direct | |||
| Michael Thomas Henderson | SYRE | Stock Option (Right to Buy) | Award | 8,026 | 8,026 | 27 May 2026 | Direct | |||
| Laurie Stelzer | SYRE | Stock Option (Right to Buy) | Award | 8,026 | 8,026 | 27 May 2026 | Direct | |||
| Mark C. McKenna | SYRE | Stock Option (Right to Buy) | Award | 8,026 | 8,026 | 27 May 2026 | Direct | |||
| Sandra Milligan | SYRE | Stock Option (Right to Buy) | Award | 8,026 | 8,026 | 27 May 2026 | Direct | |||
| Michael Thomas Henderson | SYRE | Common Stock | Sale | -47.4% | $5,952,050 | $74.40 | -80,000 | 88,606 | 08 May 2026 | Direct |
| Scott L. Burrows | SYRE | Common Stock | Sale | -11.3% | $892,125 | $71.37 | -12,500 | 97,994 | 01 May 2026 | Direct |
| Scott L. Burrows | SYRE | Common Stock | Options Exercise | 12.8% | 12,500 | 110,494 | 01 May 2026 | Direct | ||
| Scott L. Burrows | SYRE | Stock Option (Right to Buy) | Options Exercise | -3.17% | -12,500 | 382,357 | 01 May 2026 | Direct | ||
| Sheldon Sloan | SYRE | Common Stock | Sale | -100% | $5,600,701 | $71.50 | -78,333 | 0 | 01 May 2026 | Direct |
| Sheldon Sloan | SYRE | Common Stock | Options Exercise | 78,333 | 78,333 | 01 May 2026 | Direct | |||
| Sheldon Sloan | SYRE | Stock Option (Right to Buy) | Options Exercise | -19.6% | -78,333 | 321,667 | 01 May 2026 | Direct | ||
| Cameron Turtle | SYRE | Common Stock | Sale | -2.39% | $1,070,507 | $71.37 | -15,000 | 612,540 | 01 May 2026 | Direct |
| Cameron Turtle | SYRE | Common Stock | Sale | -2.33% | $739,912 | $49.33 | -15,000 | 627,540 | 01 Apr 2026 | Direct |
| Sheldon Sloan | SYRE | Common Stock | Sale | -100% | $397,900 | $50.00 | -7,958 | 0 | 01 Apr 2026 | Direct |
| Sheldon Sloan | SYRE | Common Stock | Options Exercise | 7,958 | 7,958 | 01 Apr 2026 | Direct | |||
| Sheldon Sloan | SYRE | Stock Option (Right to Buy) | Options Exercise | -8.33% | -7,958 | 87,542 | 01 Apr 2026 | Direct | ||
| Scott L. Burrows | SYRE | Common Stock | Sale | -7.11% | $370,076 | $49.34 | -7,500 | 97,994 | 01 Apr 2026 | Direct |
| Scott L. Burrows | SYRE | Common Stock | Options Exercise | 7.65% | 7,500 | 105,494 | 01 Apr 2026 | Direct | ||
| Scott L. Burrows | SYRE | Stock Option (Right to Buy) | Options Exercise | -1.86% | -7,500 | 394,857 | 01 Apr 2026 | Direct | ||
| Scott L. Burrows | SYRE | Common Stock | Sale | -2.49% | $101,620 | $40.65 | -2,500 | 97,994 | 03 Mar 2026 | Direct |
| Scott L. Burrows | SYRE | Common Stock | Options Exercise | 2.55% | 2,500 | 100,494 | 03 Mar 2026 | Direct | ||
| Scott L. Burrows | SYRE | Stock Option (Right to Buy) | Options Exercise | -0.62% | -2,500 | 402,357 | 03 Mar 2026 | Direct | ||
| Cameron Turtle | SYRE | Common Stock | Sale | -2.28% | $632,866 | $42.19 | -15,000 | 642,540 | 02 Mar 2026 | Direct |
| Cameron Turtle | SYRE | Common Stock | Sale | -2.23% | $492,045 | $32.80 | -15,000 | 657,540 | 02 Feb 2026 | Direct |
| Michael Thomas Henderson | SYRE | Common Stock | Other | 60% | 63,227 | 168,606 | 21 Jan 2026 | Direct | ||
| Scott L. Burrows | SYRE | Stock Option (Right to Buy) | Award | 140,000 | 140,000 | 09 Jan 2026 | Direct | |||
| Cameron Turtle | SYRE | Stock Option (Right to Buy) | Award | 528,000 | 528,000 | 09 Jan 2026 | Direct | |||
| Sheldon Sloan | SYRE | Stock Option (Right to Buy) | Award | 140,000 | 140,000 | 09 Jan 2026 | Direct | |||
| Heidy King-Jones | SYRE | Stock Option (Right to Buy) | Award | 140,000 | 140,000 | 09 Jan 2026 | Direct | |||
| Cameron Turtle | SYRE | Common Stock | Sale | -2.18% | $460,134 | $30.68 | -15,000 | 671,907 | 02 Jan 2026 | Direct |
| Cameron Turtle | SYRE | Common Stock | Sale | -2.14% | $435,356 | $29.02 | -15,000 | 686,907 | 01 Dec 2025 | Direct |
| Cameron Turtle | SYRE | Common Stock | Sale | -6.02% | $1,049,778 | $23.33 | -45,000 | 701,907 | 03 Nov 2025 | Direct |
| Scott L. Burrows | SYRE | Common Stock | Sale | -15.8% | $299,639 | $16.26 | -18,428 | 97,994 | 02 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.